Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy Celularity (NASDAQ: CELU) entered definitive agreements to grant an exclusive license for its commercial-stage placental-derived biomaterials and certain development-stage programs, with upfront and milestone payments totaling up to $35 million and potential future royalties.Celularity will remain the exclusive manufacturer at its Florham Park FDA-compliant facility, creating ongoing manufacturing revenue, and will realign operations to focus on longevity-focused cellular therapeutics and capital efficiency.

#CELU #CELUW Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

www.stocktitan.net/news/CELU/celularity-sec...

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE

#CELU #CELUW Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

www.stocktitan.net/news/CELU/celularity-ceo...

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision Celularity (Nasdaq: CELU) entered binding term sheets for financing expected to provide up to $12.0 million in private capital to support priorities in longevity and preservation of human performance.Under the term sheets, Celularity expects initial proceeds of $10.0 million, comprising a $7.0 million senior secured term loan with a first‑priority lien on substantially all assets and secured convertible notes of up to $5.0 million convertible at $1.66 per share. The company will also issue warrants equal to 33% of the as‑converted principal, exercisable after six months at $2.00 per share. Transactions are private placements and contingent on definitive agreements.

#CELU #CELUW Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

www.stocktitan.net/news/CELU/celularity-rea...

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care Celularity (Nasdaq: CELU) announced a strategic partnership with DefEYE, including an exclusive sublicense and pricing arrangement tied to Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity round.DefEYE, formed from Verséa Ophthalmics leadership, reported ~70% sales growth in 2024 and plans to use funding to launch decellularized ophthalmic biologics including Biovance, Biovance 3L, Interfyl and related R&D. Celularity will be DefEYE’s exclusive contract manufacturer for the ophthalmic portfolio and retains the right to name one of five board members.

#CELU #CELUW Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

www.stocktitan.net/news/CELU/celularity-and...

Biotech Celularity Faces Nasdaq Compliance Challenge Over Two Missing Quarterly Reports Celularity notified of non-compliance with Nasdaq listing rules due to delayed Q1 and Q2 2025 filings. Company has until Sept 5 to update compliance plan, with final deadline of Nov 17.

#CELU #CELUW Celularity Receives Nasdaq Notice Regarding Form 10-Q

www.stocktitan.net/news/CELU/celularity-rec...

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt Celularity (NASDAQ:CELU) has completed a significant balance sheet restructuring, successfully retiring all $41.6 million in senior secured debt, including $32.0 million in principal and $9.6 million in unpaid interest. The company executed this through an Asset Purchase Agreement with Celeniv Pte. Ltd., selling its intellectual property assets while maintaining exclusive licensing rights for 5 years with renewal options.The transaction included a $33.8 million consideration used to retire debt from RWI and a Promissory Note from Mr. Lim. Additionally, Celularity completed an internal restructuring, creating six wholly-owned subsidiaries for its commercial units: biomaterials, longevity cell therapy, biobanking, contract manufacturing, discovery & development, and asset holding.

#CELU #CELUW Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

www.stocktitan.net/news/CELU/celularity-com...

Florida's New Stem Cell Law: Celularity and Fountain Life Team Up to Revolutionize Patient Care Groundbreaking partnership enables immediate deployment of stem cell treatments across Florida's longevity centers. See how this changes patient care.

#CELU #CELUW Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

www.stocktitan.net/news/CELU/celularity-fou...

Florida Makes History: New Law Unleashes Stem Cell Treatments, Celularity Positioned as Key Provider New Florida legislation enables immediate stem cell therapy access for orthopedics, wound care, and pain management. Celularity's FDA-registered facility ready to supply. Learn more.

#CELU #CELUW Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

www.stocktitan.net/news/CELU/celularity-hai...

Celularity Announces Sudden CFO Departure, Taps Internal Talent and External Advisory Firm Celularity appoints interim CFO and engages CFO Squad for financial advisory support. Learn about the leadership transition plan and immediate stability measures. See details.

#CELU #CELUW Celularity Announces Chief Financial Officer Transition

www.stocktitan.net/news/CELU/celularity-ann...

Revolutionary Stem Cell Breakthrough: New Technology Could Transform Eye Disease Treatment Novel tri-layer biomaterial shows promise in treating eye surface disorders. Research reveals superior cell growth and potential beyond ophthalmology. See clinical implications.

#CELU #CELUW Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

www.stocktitan.net/news/CELU/celularity-ann...

Celularity notified of Nasdaq non-compliance (NASDAQ:CELUW) Celularity (CELUW) faces Nasdaq non-compliance for delayed quarterly report.

Celularity notified of Nasdaq non-compliance

seekingalpha.com/news/4454022-celularity-...

#celuw

Result Details

Celularity Gets 60 Days to Fix Nasdaq Compliance After Missing Q1 Filing Deadline Biotech firm has until July 2025 to submit compliance plan following delayed Q1 report. No immediate impact on stock listing. See recovery timeline.

#CELU #CELUW Celularity Receives Nasdaq Notice Regarding Form 10-Q

www.stocktitan.net/news/CELU/celularity-rec...

Celularity Announces Full Year 2024 Operating and Financial Results Celularity (NASDAQ: CELU) reported strong financial results for FY2024, with net revenues reaching $54.2 million, marking a significant 138.1% increase from the previous year. The growth was primarily driven by a 168.7% increase in wound care product sales, contributing $22.2 million to the revenue increase. Operating expenses decreased by 57% to $92.6 million, mainly due to the absence of goodwill and IPR&D impairments. The company's loss from operations improved substantially, decreasing by 80.1% to $38.4 million. The Biovance® product line showed particularly strong performance, and the company received recommendation letters from the FDA Tissue Reference Group for additions to their placental-derived biomaterial products portfolio.

#CELU #CELUW Celularity Announces Full Year 2024 Operating and Financial Results

www.stocktitan.net/news/CELU/celularity-ann...

CMS Extends Medicare Coverage for Wound Care Products: Major Win for Skin Substitute Market CMS postpones Medicare coverage changes for wound care products to 2026, maintaining current reimbursement. Key victory for skin substitute manufacturers and patients.

#CELU #CELUW Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

www.stocktitan.net/news/CELU/celularity-wel...

Celularity Secures Crucial FDA Pathway for Wound Care Products - Can They Capture Share of $810M Market? Celularity receives FDA HCT/P 361 status for Natalin and Acelagraft wound care products, positioning the company in the $347M biological skin substitutes market.

#CELU #CELUW Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

www.stocktitan.net/news/CELU/celularity-rec...

Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential? Strategic partnership enables BlueSphere Bio's TCR T cell therapy production at Celularity's state-of-the-art facility, marking second major manufacturing deal

#CELU #CELUW Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

www.stocktitan.net/news/CELU/celularity-ent...

Celularity Restores Nasdaq Compliance After Major Financial Reporting Overhaul Celularity regains Nasdaq listing compliance following strategic improvements to financial reporting, including partnership with EisnerAmper LLP and enhanced internal controls.

#CELU #CELUW Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

#stocks #StockMarket #news

www.stocktitan.net/news/CELU/celularity-inc...

Celularity Reports Explosive 621% Product Sales Growth, Returns to Nasdaq Compliance | CELU Stock News Celularity achieves remarkable growth with 238% revenue surge to $36.1M, led by record product sales. Company regains Nasdaq compliance with latest quarterly filing.

#CELU #CELUW Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

#news #stocks #StockMarket

www.stocktitan.net/news/CELU/celularity-rep...

Celularity Faces Nasdaq Non-Compliance Notice Over Delayed Q3 Filing | CELU Stock News Celularity must submit compliance plan by Jan 2025 following Nasdaq warning over Q3 filing delay. Company cites reporting backlog but expects to file shortly.

#CELU #CELUW Celularity Inc. Announces Receipt of Nasdaq Notification

#news #StockMarket #investing

www.stocktitan.net/news/CELU/celularity-inc...

#CELU #CELUW Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

www.stocktitan.net/news/CELU/celularity-s-s...

#CELU #CELUW Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

www.stocktitan.net/news/CELU/celularity-inc...